GlassScriptPhysician profile
Kaitlyn Wendolowski
NPI 1033728100
$2,345.10
in general payments reported to CMS, 2019-2025
31 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $903 · 2022: $1,115 · 2023: $37.67 · 2024: $15.68 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $955.77 | 2021-2025 | Ozempic |
| Abbvie INC. | $256.08 | 2021-2022 | |
| Amgen INC. | $129.52 | 2021-2022 | |
| Exact Sciences Corporation | $96.49 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $90.34 | 2021-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.27 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $84.70 | 2021-2025 | Mounjaro, Zepbound |
| Insulet Corporation | $70.93 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $63.49 | 2022 | |
| Dexcom, INC. | $58.93 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.52 | 2021-2022 | |
| Becton, Dickinson and Company | $34.64 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.99 | 2022 | |
| Glaxosmithkline, LLC. | $31.29 | 2021-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $26.35 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $23.96 | 2022 | |
| Sanofi Pasteur INC. | $23.93 | 2023 | |
| Sumitomo Pharma America, INC. | $22.97 | 2025 | Gemtesa |
| Beta Bionics, INC. | $22.93 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Vifor Pharma, INC. | $16.47 | 2021 | |
| Lundbeck LLC | $16.37 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $16.08 | 2021 | |
| Currax Pharmaceuticals LLC | $15.55 | 2021 | |
| Pfizer INC. | $14.94 | 2021 | |
| Harmony Biosciences LLC | $14.81 | 2025 | |
| Esperion Therapeutics, INC. | $14.33 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.88 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.81 | 2021 | |
| Radius Health, INC. | $13.52 | 2022 | |
| Mannkind Corporation | $12.19 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Wendolowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.